The management of Human Immunodeficiency Virus-1 (HIV-1) infection has undergone dramatic change since its initial identification. Advances have occurred in drug development, viral pathology understanding, laboratory monitoring and genetic analysis. With the advent of highly active antiretroviral therapy (HAART), there has been a substantial decline in HIV-1-related morbidity and mortality. Today, HIV-1 infection is treated as a chronic disease that requires strict patient adherence to HAART. Pharmacists provide pharmaceutical care to patients with HIV disease in a variety of ways, and they can improve patient adherence rates. Current therapeutic strategies have not resulted in eradication of HIV-1 infection. Present and future therapeutic challenges include viral resistance, reservoirs of virus and drug toxicities. Globally, the spread of HIV-1 infection continues at an alarming rate, and economic and social barriers may limit access and success of HAART. New strategies and novel approaches in managing HIV-1 infection continue to be developed in an effort to cure and eradicate this disease.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-739.
2.
Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996; 334:1011-1917.
3.
Hogg RS, Health KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998; 279:450-454.
4.
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-860.
5.
Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med. 1998; 129:503-504.
6.
Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
7.
Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999; 340:1614-1622.
8.
Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999; 340:1605-1613.
9.
Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1294.
10.
Department of Health and Human Services/Henry J Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, MD: HIV/AIDS Treatment Information Service, January, 2000 (available online at http://www.hivatis.org/trtgdlns.html).
11.
Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults—updated recommendations of the international AIDS society—USA panel. JAMA. 2000; 283:381-390.
12.
Glaxo Wellcome. Zidovudine (Retrovir) product information brochure. Research Triangle Park, NC; 1998.
13.
Bristol-Myers Squibb. Didanosine (Videx) product information brochure. Princeton, NJ; 1999.
Roche Laboratories. Saquinavir (Fortovase) product information brochure. Nutley, NJ; 1997.
26.
Abbott Laboratories. Ritonavir (Norvir) product information brochure. North Chicago, IL; 2000.
27.
Merck Laboratories. Indinavir (Crixivan) product information brochure. West Point, PA; 2000.
28.
Agouron Pharmaceuticals. Nelfinavir (Viracept) product information brochure. La Jolla, CA; 2000.
29.
Glaxo Wellcome. Amprenavir (Agenerase) product information brochure. Research Triangle Park, NC; 2000.
30.
Abbott Laboratories. Lopinavir/Ritonavir (Kaletra) product information brochure. North Chicago, IL; 2000.
31.
Debouck C.The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retro-viruses. 1992; 8:153-164.
32.
Deeks S, Volberding P.An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract. 1995; 30 (suppl 1): 23-31.
33.
Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1998; 47:1-30.
34.
Public Health Science Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. Centers for Disease Control and Prevention. MMRW Morb Mortal Wkly Rep. 1998; 47:1-33.
35.
Havilar DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis. 2000; 182:321-325.
36.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
Hirsch MS, Brun-Vezinet F, D’Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. JAMA. 2000; 283:2417-2426.
39.
Pozniak A, Gazzard BG, Churchill D, et al. British HIV association (BHIVA) guideline for the treatment of HIV-infected adults with antiretroviral therapy. London: BHIVA, December 1999 (available online at www.aidsmap.com/bhiva/bhivagd1299.htm).
40.
National Program on STD/AIDS, Secretariat for Health Policy. Recommendations on antiretroviral therapy for HIV-infected adults and adolescents. Brasilia: Ministry of Health, 1999.
41.
Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet. 2000; 355:2147-2152.
42.
Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS. 1998; 12:71-77.
43.
Lori F.Hydroxyurea and HIV: 5 years later—from antiviral to immune-modulating effects. AIDS. 1999; 13:1433-1442.
44.
Gibbs MA, Sorensen SJ. Hydroxyurea in the treatment of HIV-1. Ann Pharmacother. 2000; 34:89-93.
45.
Hoen B, Dumon B, Harzic M, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 Trial. J Infect Dis. 1999; 180:1342-1346.
46.
Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. JInfect Dis. 1997; 175:1051-1055.
47.
Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS. 1999; 13:791-796.
48.
Wainberg MA, Friedland G.Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998; 279:1977-1983.
49.
Kastrissios H, Suarez JR, Katzenstein D, et al. Characterization patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998; 12:2295-2303.
50.
Crespo-Fiero M.Compliance/adherence and care management in HIV disease. J of the Association of Nurses in AIDS Care. 1997; 8:43-54.
51.
Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000; 23:386-395.
52.
Clough LA, D’Agata E, Raffanti S, et al. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis. 1999; 29:75-81.
53.
Chesney M.Adherence to antiretroviral therapy. 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Presentation 281, session B25.
54.
Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998; 13:586-593.
55.
DiMatteo MR, Reiter RC, Gambone JC. Enhancing medication adherence through communication and informed collaborative choice. Health Communication. 1994; 6:253-265.
56.
Ballard-Reisch, DS. A model of participative decision making for physician-patient interaction. Health Communication. 1990; 2:91-104.
57.
Kaplan RM. Health-related quality of life in patient decision-making. J Social Issues. 1991; 47:69-70.
58.
UNAIDS: AIDS epidemic update: December 1999.
59.
The role of the pharmacist in the fight against the HIV-AIDS pandemic. International Pharmacy Journal. 1997; 11:IV.
